Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS · Delayed Price · Currency is USD
0.0428
-0.0175 (-29.02%)
At close: Oct 9, 2026
Emmaus Life Sciences Revenue
Emmaus Life Sciences had revenue of $6.32M in the quarter ending June 30, 2026, with 124.28% growth. This brings the company's revenue in the last twelve months to $15.53M, up 10.98% year-over-year. In the year 2025, Emmaus Life Sciences had annual revenue of $12.45M, down -25.22%. That makes Emmaus Life Sciences the 35,179th largest company in the world by revenue and 4,644th in the United States.
Revenue (ttm)
15.53M
Revenue Growth
+10.98%
P/S Ratio
0.19
Revenue / Employee
470.61K
Employees
33
Market Cap
3.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.45M | -4.20M | -25.22% |
| Dec 31, 2024 | 16.65M | -12.94M | -43.73% |
| Dec 31, 2023 | 29.60M | 11.21M | 60.94% |
| Dec 31, 2022 | 18.39M | -2.22M | -10.77% |
| Dec 31, 2021 | 20.61M | -2.56M | -11.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pacific Software | 2.40M |
| Orgenesis | 1.04M |
| TRON Group | 1.01M |
| Vaccinex | 601.00K |
| America Great Health | 363.33K |
| Eastgate Biotech | 137.64K |
| Aditxt | 14.34K |
Emmaus Life Sciences News
- 5 weeks ago - Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer - Business Wire
- 1 month ago - Emmaus Life Sciences Reports Quarterly Financial Results - Business Wire
- 6 months ago - Emmaus Life Sciences Reports Annual Financial Results - Business Wire
- 9 months ago - Emmaus Life Sciences enters license, distribution agreement with NeoImmuneTech - TheFly
- 9 months ago - Emmaus Life Sciences Announces Strategic Transaction - Business Wire
- 1 year ago - Emmaus Life Sciences receives FDA approval for Endari label changes - TheFly
- 1 year ago - Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports Improved Quarterly Financial Results - PRNewsWire